MADRIGAL PHARMACEUTICALS, INC. Earnings Per Share (Basic)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Earnings Per Share (Basic) of -$1.99 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$1.99.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$3.25.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$4.01.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$1.50.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$17.23.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2021 was -$14.63.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2020 was -$13.09.
- MADRIGAL PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2011 was -$1.00.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.99 10-Q · filed 2026-07-30 | -$5.24 10-Q · filed 2026-07-30 | ||||||
| 2026-03-31 | -$3.25 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | -$10.15 10-Q · filed 2026-07-30 | -$12.85 10-K · filed 2026-02-19 | ||||||
| 2025-09-30 | -$4.01 10-Q · filed 2026-07-30 | -$5.08 10-Q · filed 2025-11-04 | -$8.12 10-Q · filed 2026-07-30 | -$10.32 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | -$1.50 10-Q · filed 2026-07-30 | -$1.90 10-Q · filed 2025-08-05 | -$4.10 10-Q · filed 2026-07-30 | -$5.22 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | -$2.61 10-Q · filed 2026-05-06 | -$3.32 10-Q · filed 2025-05-01 | ||||||
| 2024-12-31 | -$17.31 10-Q · filed 2026-07-30 | -$21.90 10-K · filed 2025-02-26 | ||||||
| 2024-09-30 | -$4.92 10-Q · filed 2025-11-04 | -$19.31 10-Q · filed 2025-11-04 | ||||||
| 2024-06-30 | -$7.10 10-Q · filed 2025-08-05 | -$14.47 10-Q · filed 2025-08-05 | ||||||
| 2024-03-31 | -$7.38 10-Q · filed 2025-05-01 | |||||||
| 2023-12-31 | -$5.68 10-K · filed 2024-02-28 | -$17.33 10-Q · filed 2026-07-30 | -$19.99 10-K · filed 2024-02-28 | |||||
| 2023-09-30 | -$5.34 10-Q · filed 2024-10-31 | -$14.27 10-Q · filed 2024-10-31 | ||||||
| 2023-06-30 | -$4.69 10-Q · filed 2024-08-07 | -$8.91 10-Q · filed 2024-08-07 | ||||||
| 2023-03-31 | -$4.23 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | -$4.98 10-K · filed 2024-02-28 | -$17.23 10-K · filed 2025-02-26 | ||||||
| 2022-09-30 | -$4.75 10-K · filed 2024-02-28 | -$12.25 10-Q · filed 2023-11-06 | ||||||
| 2022-06-30 | -$4.14 10-K · filed 2024-02-28 | -$7.50 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | -$3.36 10-K · filed 2024-02-28 | |||||||
| 2021-12-31 | -$3.78 10-K/A · filed 2023-03-03 | -$14.63 10-K · filed 2024-02-28 | ||||||
| 2021-09-30 | -$3.79 10-K/A · filed 2023-03-03 | -$10.84 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | -$3.72 10-K/A · filed 2023-03-03 | -$7.05 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$3.32 10-K/A · filed 2023-03-03 | |||||||
| 2020-12-31 | -$13.09 10-K/A · filed 2023-03-03 | |||||||
| 2012-03-31 | -$0.27 derived: net income ÷ weighted average shares · filed 2014-03-11 | -$0.43 derived: net income ÷ weighted average shares · filed 2014-03-11 | -$0.72 derived: net income ÷ weighted average shares · filed 2014-03-11 | -$1.00 derived: net income ÷ weighted average shares · filed 2014-03-11 | ||||
| 2011-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.45 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.74 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$1.00 10-K · filed 2012-02-22 | ||||
| 2011-09-30 | -$0.30 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.60 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.87 derived: net income ÷ weighted average shares · filed 2012-11-06 | -$1.08 derived: net income ÷ weighted average shares · filed 2013-03-14 | ||||
| 2011-06-30 | -$0.30 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.57 derived: net income ÷ weighted average shares · filed 2012-08-02 | -$0.78 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$1.04 derived: net income ÷ weighted average shares · filed 2013-03-14 | ||||
| 2011-03-31 | -$0.27 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.49 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.74 derived: net income ÷ weighted average shares · filed 2013-03-14 | |||||
| 2010-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.47 derived: net income ÷ weighted average shares · filed 2013-03-14 | -$0.93 10-K · filed 2012-02-22 | |||||
| 2010-09-30 | -$0.25 derived: net income ÷ weighted average shares · filed 2011-11-03 | -$0.71 derived: net income ÷ weighted average shares · filed 2011-11-03 | ||||||
| 2009-12-31 | $2.33 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |